SG10201912199XA - Anti-tim-3 antibodies and use thereof - Google Patents
Anti-tim-3 antibodies and use thereofInfo
- Publication number
- SG10201912199XA SG10201912199XA SG10201912199XA SG10201912199XA SG10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA
- Authority
- SG
- Singapore
- Prior art keywords
- tim
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016096924 | 2016-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201912199XA true SG10201912199XA (en) | 2020-02-27 |
Family
ID=61246369
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912199XA SG10201912199XA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
SG11201901548SA SG11201901548SA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901548SA SG11201901548SA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
Country Status (16)
Country | Link |
---|---|
US (3) | US11203637B2 (ja) |
EP (2) | EP3504243B1 (ja) |
JP (2) | JP6968872B2 (ja) |
KR (1) | KR102460525B1 (ja) |
CN (3) | CN116655790A (ja) |
AU (1) | AU2017317227B2 (ja) |
BR (1) | BR112019003976A2 (ja) |
CA (1) | CA3034962A1 (ja) |
EA (1) | EA201990594A1 (ja) |
IL (1) | IL264970B1 (ja) |
MX (1) | MX2019002242A (ja) |
NZ (1) | NZ751246A (ja) |
SG (2) | SG10201912199XA (ja) |
TW (1) | TWI769174B (ja) |
WO (1) | WO2018036561A1 (ja) |
ZA (1) | ZA201901113B (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016005408B1 (pt) * | 2013-09-13 | 2023-03-21 | Beigene Switzerland Gmbh | Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral |
EP3160505A4 (en) | 2014-07-03 | 2018-01-24 | BeiGene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
CN109757103B (zh) | 2016-07-14 | 2024-01-02 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
MX2019002242A (es) | 2016-08-26 | 2019-08-16 | Beigene Ltd | Anticuerpos anti-tim-3 y uso de los mismos. |
CN110062885A (zh) | 2016-11-01 | 2019-07-26 | 安奈普泰斯生物有限公司 | 针对t细胞免疫球蛋白和粘蛋白3(tim-3)的抗体 |
AU2018205401A1 (en) | 2017-01-09 | 2019-07-25 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
WO2019001417A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA |
AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
WO2019179420A1 (en) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-tim-3 antibodies |
TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
US11807683B2 (en) | 2018-04-12 | 2023-11-07 | Nanjing Leads Biolabs Co., Ltd. | Antibody binding TIM-3 and use thereof |
MX2021001516A (es) * | 2018-08-20 | 2021-04-19 | Jiangsu Hengrui Medicine Co | Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores. |
KR20210045999A (ko) * | 2018-08-21 | 2021-04-27 | 앨버트 아인슈타인 컬리지 오브 메디신 | 인간 Tim-3에 대한 모노클로날 항체 |
KR20220016156A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐 |
EP3976832A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
US20230279105A1 (en) * | 2019-06-21 | 2023-09-07 | Single Cell Technology, Inc. | Anti-tim-3 antibodies |
CN110498855A (zh) * | 2019-07-25 | 2019-11-26 | 钟小泉 | 一种tim-3抗体及其用途 |
BR112022008184A2 (pt) * | 2019-11-21 | 2022-07-12 | Beigene Ltd | Métodos de tratamento do câncer e para aumentar, potencializar ou estimular uma resposta ou função imune |
CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术(上海)有限公司 | 抗tigit的抗体、其制备方法和应用 |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
JP2024503265A (ja) | 2020-12-28 | 2024-01-25 | ブリストル-マイヤーズ スクイブ カンパニー | 抗体組成物およびその使用の方法 |
MX2023007650A (es) | 2020-12-28 | 2023-09-11 | Bristol Myers Squibb Co | Metodos de tratamiento de tumores. |
CN112940127A (zh) * | 2021-03-12 | 2021-06-11 | 北京广未生物科技有限公司 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
EP4326773A1 (en) * | 2021-04-23 | 2024-02-28 | Suzhou Neologics Bioscience Co., Ltd. | Tim-3-targetting antibodies and uses thereof |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024041651A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies |
WO2024041652A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment |
WO2024044675A1 (en) | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies |
WO2024184812A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 antibodies and methods of use |
WO2024184811A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cd3 multispecific antibodies and methods of use |
WO2024184810A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use |
CN117777306B (zh) * | 2023-07-04 | 2024-08-20 | 深圳豪石生物科技有限公司 | 一种靶向cldn18.2的增强型嵌合抗原受体及其用途 |
CN117777307B (zh) * | 2023-09-26 | 2024-08-20 | 深圳豪石生物科技有限公司 | 一种cldn18.2特异性嵌合t细胞受体、嵌合t细胞受体免疫细胞及其应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US7563874B2 (en) | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
EP1406653A4 (en) * | 2001-06-29 | 2005-05-04 | Univ Leland Stanford Junior | T-LYMPHOCYTE REGULATORY GENES AND METHODS OF USE |
CA2474497C (en) | 2002-01-30 | 2013-12-03 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to tim-3, a th1-specific cell surface molecule |
JP2011500730A (ja) | 2007-10-26 | 2011-01-06 | ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント | Tim−3を用いた治療および診断方法 |
EP2303926A1 (en) | 2008-06-20 | 2011-04-06 | Oklahoma Medical Research Foundation | Immunogenic memapsin 2 -secretase peptides and methods of use |
EP3363499A1 (en) * | 2010-06-11 | 2018-08-22 | Kyowa Hakko Kirin Co., Ltd. | Anti-tim-3 antibody |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
CN102492038B (zh) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | 抗人Tim-3的中和性单克隆抗体L3D及其用途 |
AU2014312310A1 (en) * | 2013-08-28 | 2016-04-07 | Abbvie Stemcentrx Llc | Novel SEZ6 modulators and methods of use |
BR112016005408B1 (pt) | 2013-09-13 | 2023-03-21 | Beigene Switzerland Gmbh | Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral |
CN103721255A (zh) | 2014-01-07 | 2014-04-16 | 苏州大学 | 共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途 |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
EP3160505A4 (en) * | 2014-07-03 | 2018-01-24 | BeiGene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
AU2015340056A1 (en) * | 2014-10-27 | 2017-05-25 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
LT3215532T (lt) | 2014-11-06 | 2020-01-10 | F. Hoffmann-La Roche Ag | Anti-tim3 antikūnai ir jų naudojimo būdai |
MX2019002242A (es) | 2016-08-26 | 2019-08-16 | Beigene Ltd | Anticuerpos anti-tim-3 y uso de los mismos. |
-
2017
- 2017-08-25 MX MX2019002242A patent/MX2019002242A/es unknown
- 2017-08-25 BR BR112019003976A patent/BR112019003976A2/pt unknown
- 2017-08-25 EA EA201990594A patent/EA201990594A1/ru unknown
- 2017-08-25 US US16/328,047 patent/US11203637B2/en active Active
- 2017-08-25 SG SG10201912199XA patent/SG10201912199XA/en unknown
- 2017-08-25 IL IL264970A patent/IL264970B1/en unknown
- 2017-08-25 EP EP17842983.3A patent/EP3504243B1/en not_active Withdrawn - After Issue
- 2017-08-25 EP EP21190971.8A patent/EP3970749A1/en active Pending
- 2017-08-25 AU AU2017317227A patent/AU2017317227B2/en active Active
- 2017-08-25 SG SG11201901548SA patent/SG11201901548SA/en unknown
- 2017-08-25 CN CN202310121523.0A patent/CN116655790A/zh active Pending
- 2017-08-25 CN CN202310121525.XA patent/CN116478290A/zh active Pending
- 2017-08-25 NZ NZ751246A patent/NZ751246A/en unknown
- 2017-08-25 KR KR1020197007868A patent/KR102460525B1/ko active IP Right Grant
- 2017-08-25 WO PCT/CN2017/099098 patent/WO2018036561A1/en unknown
- 2017-08-25 CA CA3034962A patent/CA3034962A1/en active Pending
- 2017-08-25 JP JP2019511565A patent/JP6968872B2/ja active Active
- 2017-08-25 CN CN201780052246.5A patent/CN109790218B/zh active Active
- 2017-08-25 TW TW106129066A patent/TWI769174B/zh active
-
2019
- 2019-02-21 ZA ZA2019/01113A patent/ZA201901113B/en unknown
-
2021
- 2021-10-27 JP JP2021175867A patent/JP7158552B2/ja active Active
- 2021-11-15 US US17/526,817 patent/US20220135675A1/en not_active Abandoned
-
2023
- 2023-09-27 US US18/475,552 patent/US20240076375A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL264970A (en) | Anti-tim-3 antibodies and their use | |
IL290842A (en) | Anti-cd73 antibodies and uses thereof | |
IL268206A (en) | Antibodies directed against bcma and their use | |
IL262095A (en) | Anti-pacap antibodies and their use | |
ZA202102905B (en) | Anti-galectin-9 antibodies and uses thereof | |
ZA202101318B (en) | Anti-phf-tau antibodies and uses thereof | |
IL268734A (en) | Anti-LAG-3 antibodies and uses thereof | |
EP3541840C0 (en) | ANTI-HLA-G ANTIBODIES AND THEIR USE | |
IL271477A (en) | Anti-cd166 antibodies and their uses | |
IL269134A (en) | Antibodies against PAR2 and their use | |
ZA201901935B (en) | Anti-il-33 antibodies and uses thereof | |
IL247315A0 (en) | Anti-acth antibodies and their uses | |
IL263242A (en) | Cytosol-penetrating antibody and use thereof | |
IL266049A (en) | Antibodies against o1 and their uses | |
IL272476A (en) | Anti-Apelin antibodies and their uses | |
IL264417A (en) | Anti-o2 antibodies and their uses | |
IL273157A (en) | Antibodies specific to AXL and their uses | |
IL271398A (en) | Anti-l1-cam antibodies and uses thereof | |
IL266082A (en) | Anti-chikv antibodies and their use | |
SG11202003585VA (en) | Anti-vista antibody and use thereof | |
ZA201906248B (en) | Anti-ceacam1 antibody and use thereof | |
GB201712032D0 (en) | Antibodies and uses thereof |